Wide Ranks

INMB

INmune Bio Inc.

4.89

Top Statistics
Market Cap 108 M Forward PE -2.39 Revenue Growth 0.00 %
Current Ratio 2.59 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue 1852.01 Price To Sales Trailing12 Months 2581.51
Profitability
Profit Margins 0.00 % Operating Margins -98921.43 %
Balance Sheet
Total Cash 33 M Total Cash Per Share 1.51 Total Debt 2 M
Total Debt To Equity 7.53 Current Ratio 2.59 Book Value Per Share 1.74
All Measures
Short Ratio 1496.00 % Message Board Id finmb_530336663 Shares Short Prior Month 2 M
Return On Equity -0.9896 City Boca Raton Uuid c2bc9e2c-bd0f-3696-b923-dcb9898acbf0
Previous Close 4.88 First Trade Date Epoch Utc 1 B Book Value 1.74
Beta 1.85 Total Debt 2 M Volume 171503
Price To Book 2.80 Fifty Two Week Low 4.45 Total Cash Per Share 1.51
Total Revenue 42000 Shares Short Previous Month Date 1 B Target Median Price 20.50
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -98921.43 %
Target Mean Price 19.83 Net Income To Common -41272000 Short Percent Of Float 0.2017
Implied Shares Outstanding 22 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 203070 Average Volume10days 203070 Total Cash 33 M
Next Fiscal Year End 1 B Revenue Per Share 0.0020 Held Percent Insiders 0.2873
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 4.88 Target Low Price 16.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.35 Open 4.99 Free Cashflow -10763875
State FL Dividend Yield 0.00 % Return On Assets -0.4497
Time Zone Short Name EST Trailing Eps -2.18 Day Low 4.88
Address1 225 NE Mizner Blvd. Shares Outstanding 22 M Price Hint 4
Target High Price 22.00 Website https://www.inmunebio.com 52 Week Change -0.4825
Average Volume 251198 Forward Eps -2.04 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 253.00 % Is_sp_500 False
Regular Market Day High 5.12 Profit Margins 0.00 % Debt To Equity 7.53
Fifty Two Week High 14.74 Day High 5.12 Shares Short 3 M
Regular Market Open 4.99 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1852.01 Revenue Growth 0.00 % Shares Percent Shares Out 0.1609
Operating Cashflow -25749000 Currency USD Time Zone Full Name America/New_York
Market Cap 108 M Is_nasdaq_100 False Zip 33432
Quote Type EQUITY Industry Biotechnology Long Name INmune Bio, Inc.
Regular Market Day Low 4.88 Held Percent Institutions 0.2434 Current Price 4.89
Address2 Suite 640 Financial Currency USD Current Ratio 2.59
Gross Margins 100.00 % Industry Disp Biotechnology Number Of Analyst Opinions 6
Country United States Float Shares 14 M Two Hundred Day Average 8.41
Enterprise Value 77 M Price To Sales Trailing12 Months 2581.51 Forward PE -2.39
Regular Market Volume 171503 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers.

It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression.

It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg.

INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.